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BACKGROUND. Metastases to bone are a frequent complication of human prostate cancer
and result in the development of osteoblastic lesions that include an underlying osteoclastic
component. Previous studies in rodent models of breast and prostate cancer have established
that receptor activator ofNF-kB ligand (RANKL) inhibition decreases bone lesion development
and tumor growth in bone. RANK is essential for osteoclast differentiation, activation, and
survival via its expression on osteoclasts and their precursors. RANK expression has also been
observed in some tumor cell types such as breast and colon, suggesting that RANKLmay play a
direct role on tumor cells.
METHODS. Male CB17 severe combined immunodeficient (SCID) mice were injected with
PC3 cells intratibially and treatedwith either PBS or human osteprotegerin (OPG)-Fc, a RANKL
antagonist. The formation of osteolytic lesions was analyzed by X-ray, and local and systemic
levels of RANKLandOPGwere analyzed. RANKmRNAandprotein expressionwere assessed
onmultiple prostate cancer cell lines, and events downstreamof RANKactivationwere studied
in PC3 cells in vitro.
RESULTS. OPG-Fc treatment of PC3 tumor-bearing mice decreased lesion formation and
tumor burden. Systemic and local levels of RANKL expression were increased in PC3 tumor
bearingmice. PC3 cells responded to RANKL by activatingmultiple signaling pathwayswhich
resulted in significant changes in expression of genes involved in osteolysis and migration.
RANK activation via RANKL resulted in increased invasion of PC3 cells through a collagen
matrix.
CONCLUSION. These data demonstrate that host stromal RANKL is induced systemically
and locally as a result of PC3 prostate tumor growth within the skeleton. RANK is
expressed on prostate cancer cells and promotes invasion in a RANKL-dependent manner.
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INTRODUCTION
The majority of patients with advanced prostate
cancer will develop bone metastases, and these
metastases are associated with significant morbidity
including pain, bone loss, fracture, hypercalcemia, and
bone marrow replacement [1,2]. Prostate cancer bony
metastases induce osteoblastic lesions while osteolytic
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lesions are typically observed with multiple myeloma
and breast cancer. The osteoblastic or osteolytic
character of bone metastases actually represents two
extremes of a spectrum in which dysregulation of the
normal bone remodeling process occurs [2–5]. The
notion that total bone remodeling [6] is increased
in patients with prostate cancer bone metastases is
supported by histological evidence of osteoclast action
[7] and the increases in markers of bone resorption
(e.g., N-telopeptide of type I collagen, or NTX) [8]. The
mechanisms by which tumor cells co-opt the normal
processes of bone remodeling and the reciprocal
feedback of the bone microenvironment to the bone
are central to the pathophysiology of metastatic bone
disease.
TheRANK/RANKL/OPGaxis governs osteoclasto-
genesis and bone resorption [9]. The TNF ligand
superfamily member RANKL is critical for formation,
function, and survival of osteoclasts [10,11] and exerts
its action through binding and activation of its receptor
RANK [12,13], which is expressed on the surface of
myeloid osteoclast precursors [14]. Osteprotegerin
(OPG) is a soluble member of the TNF receptor super
family secreted by osteoblasts which, by competing
with RANK for RANKL, acts as a decoy receptor
of RANKL, thereby inhibiting osteoclastogenesis. The
stimulation of osteoclastogenesis observed in bone
metastases is frequently a result of increases in RANKL
and/or decreases in OPG levels [15]. The complete
block of tumor-induced osteolytic lesions by RANKL
inhibitors (e.g., RANK-Fc or OPG-Fc) in animal models
of bone metastases demonstrates the vital role of this
factor in cancer-inducedbonedisease [16,17], including
that mediated by prostate cancer [18].
In addition to the expression of RANK on hema-
topoietic osteoclast precursors, this receptor has also
been observed in some tumor cell types [19,20] and
RANKLmay therefore play a role in the migration and
metastatic behavior of cancer in the skeleton. In this
studyweanalyzed the expression ofRANKmRNAand
protein on prostate cancer cells and demonstrated that
activation of RANK by RANKL results in multiple
downstream signaling events and changes in global




PC3, LNCaP, DU145, MDAPCa2b, and 22Rv1
prostate cancer lines were obtained from ATCC. PC3,
LNCaP, 22Rv1, andDU145 cellswere cultured in RPMI
with 10% fetal bovine serum (FBS). MDAPCa2b were
grown in BRFF HPCI with 20% FBS (Athena Enzyme
Systems, Baltimore, MD). C42B cells were obtained
from UroCor, Inc. (Oklahoma City, OK) and grown in
T-media [21].
PC3Xenograft Experiments
At 8 weeks of age, male CB17 severe combined
immunodeficient (SCID) mice (Charles River Labora-
tories,Wilmington,MA)were injectedwith 1 105 PC3
cells intratibially. Mice were treated with either PBS or
3 mg/kg human OPG-Fc (Amgen, Inc., Thousand
Oaks, CA) 3weekly subcutaneously beginning either
7 or 20 days after inoculation. The presence of osteolytic
lesions was assessed by digital X-ray (Faxitron, Wheel-
ing, IL). Tumors were allowed to progress until day
24 or 27 at which time mice were sacrificed. Lesion
area was calculated from digital images using Meta-
Morph1 Imaging software (Molecular Devices Cor-
poration, Downingtown, PA).
Histopathology
Femurs and tibias were harvested and fixed in
10% neutral-buffered formalin. Bones were decalcified
in 10% formic acid for 4 days and embedded in
paraffin. Formalin-fixed paraffin-embedded sections
were cut at 0.4 mm and stained with hematoxylin and
eosin. Tumor burden was quantified on hematoxylin
stained sections using MetaMorph1 Imaging software
(Molecular Devices Corporation). Additional sections
were stained for tartrate-resistant acid phosphatase
(TRAP) activity (Sigma-Aldrich, St. Louis, MO).
Murine RANK and murine RANKL expression
were detected using antibodies AF692 and AF462,
respectively, from R&D Systems (Minneapolis, MN).
mRNAExpressionAnalysis
Total RNA was isolated from tumor cell lines or
mouse tibias using the RNAeasyTM Kit (Qiagen,
Valencia, CA) and transcribed into cDNAusing random
hexamer priming andTaqManTMReverse Transcription
Reagents (Applied Biosystems, Inc., Foster City, CA).
Tumor cell or tibia cDNA (10 ng or 25 ng, respectively)
was analyzed for gene of interest expression using
Assay on DemandTM primer probe sets (Applied
Biosystems, Inc.). Quantitative real-time reverse trans-
criptase polymerase chain reaction (RT-PCR) was
performed using the ABI Prism 7900HT Sequence
Detection System (Applied Biosystems, Inc.). Gene
expressionwas calculated relative to b-actin expression.
Reactions were performed in triplicate.
HumanRANKProtein Expression
Surface RANK expression was determined by flow
cytometry after incubation with either 1 mg/ml mouse
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anti-RANK antibody (Amgen) or isotype control (BD
Biosciences, San Jose, CA) in 2% FBS followed by
allophycocyanin (APC)-conjugated anti-mouse secon-
dary antibody. Fluorescence was assessed using a
FAScan sorter (BD Biosciences).
ImmunoblotAnalysis and
NuclearTranslocationAssays
PC3 cells were grown in serum-free RPMI overnight
prior to stimulation with 1 mg/ml recombinant
human RANKL (Amgen) for the times indicated. For
immunoblot analysis, cells were stimulated with
RANKL and harvested in 1 cell lysis buffer (Cell
Signaling, Danvers, MA) supplemented with 1 mM
phenylmethylsulfonyl fluoride and 1 mM sodium
fluoride. The soluble fraction of whole-cell lysate
(15 mg) was separated on 8–16% Tris–Glycine gels
and electroblotted onto nitrocellulose membranes.
Membranes were blocked in 5% non-fat dry milk
and subsequently incubated with antibodies to phos-
phorylated or total ERK, JNK, or MAP kinase p38 (Cell
Signaling) at 1:1,000 overnight at 48C. Blots were
incubated in anti-rabbit horseradish peroxidase (HRP;
Santa Cruz Biotechnology, Santa Cruz, CA) at 1:2,000,
washed, and developed using electrochemilumincent
(ECL) imaging (GEHealthcare, Buckinghamshire,UK).
To measure nuclear translocation of phosphorylated
forms of p38, c-Jun, or ATF-2, cells were grown
overnight in serum-free RPMI and stimulated with
1 mg/ml RANKL (Amgen) for the times indicated.
Indirect immuofluorescence reagents from ‘‘Hit Kits’’
(Cellomics, Inc., Pittsburgh, PA) were used for cell
staining. Nuclear and cytoplasmic expression was
quantified using software from Cellomics, Inc.
Gene ExpressionAnalysis
Cells were grown in RPMI containing 10% FBS and
stimulated with 1 mg/ml human recombinant RANKL
(Amgen). mRNA was isolated with the RNAeasy Kit
(Qiagen). For microarray expression analysis, 5 mg of
total mRNA was labeled using standard protocols
(Affymetrix, Santa Clara, CA) and 10 mg biotinylated
cRNA was hybridized to Human Affymetrix U133A
chip consisting of approximately 22,000 probe sets
representing 14,500 genes. Hybridized chips were
stained and washed on an Affymetrix FS400 fluidics
station using the antibody amplification protocol and
scanned using an Affymetrix GeneArray 2500 scanner.
Scanned images were loaded into the ResolverTM
system (Rosetta Biosoftware, Seattle, WA) for analysis.
CytokineAnalysis
Cells were grown in RPMI containing 10% FBS and
stimulated with 1 mg/ml human recombinant RANKL
(Amgen). Supernatant was harvested after 48 hr.
Cytokine levels were measured using ELISAs from
R&DSystems andor theHumanCytokine/Chemokine
panel from LinCo (Billerica, MA).
Cell InvasionAssay
Recombinant human RANKL and recombinant
human OPG were obtained from PeproTech, Inc.
(RockyHill,NJ). The cell invasion assaywasperformed
as described previously [22]. Briefly, 2.5 104 PC3 cells
in 0.5 ml RPMI-1640 medium containing 1% FBS
were seeded into the upper compartment of two-layer
chamber invasion plates that were separated by
an uncoated membrane (for baseline control) or a
membrane coated with collagen matrix (BD Trans-
duction Laboratory, Bedford, MA). The cells were
cultured for 48hr followedby stainingof themembrane
with a Diff-Quik stain kit (Dade Behring, Inc, Newark,
DE). Cells were quantified by counting the numbers of
cells that penetrated the membrane in five microscopic
fields (at 200magnification) per filter. Invasive ability
was defined as the proportion of cells that invaded the
matrix-coated membrane divided by the number of
cells that migrated through the uncoated membrane
(baseline migration). The results are reported as the
mean of duplicate assays.
Statistical Analysis
Statistical analysis of data was performed using
Prism Software (GraphPad Software, San Diego, CA).
For comparison of two groups, Student’s t-test was
used. Welch’s correction of variance was used when
necessary. For data comparisons with three or more
groups, one-way analysis of variance (ANOVA) with
Tukey’s post-test was used.
RESULTS
PC3 Prostate CancerCells InduceOsteolysis
Via Increases in RANKL
It is well established that the prostate cancer cell
line PC3 promotes osteolysis in murine experimental
metastases models [23,24]. We hypothesized that PC3
cells may alter RANKL and/or OPG levels, subse-
quently leading to increased osteoclastogenesis. We
verified the extent of PC3-induced osteolytic lesions by
radiographic and histologic analysis following intra-
tibial inoculation of PC3 cells into CB17 SCID mice
(Fig. 1A,B). Osteolysis was evident by radiographic
analysis at 14 days post-inoculation (Fig. 1A). The
progression of these lesions over time was significant
(Fig. 1A;P< 0.01 forday24vs. day7 andP< 0.05 forday
24 vs. day 14). Osteolysis was associated with tumor
burden and increased numbers of osteoclasts at the
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tumor/bone interface compared with naı̈ve mice
(Fig. 1B,C). Osteoclasts were also observed within the
tumor mass (data not shown).
To determine the relative contribution of murine
host stromal RANKL versus human PC3 tumor cell
RANKL expressed at tumor sites, we analyzedRANKL
mRNA expression using mouse- and human-specific
RT-PCR primers. There was a significant increase
in mouse RANKL expression in tibias with tumor
compared with contralateral non-tumor-bearing tibias
at day 21 post-injection (Fig. 2A, P< 0.01). Human
RANKL mRNA was expressed at low levels in PC3
cells in vitro, but was not detectable in tumor-bearing
tibias of mice at day 21 (data not shown). Murine
OPGmRNAwas also significantly increased in tumor-
bearing tibias (Fig. 2A, P< 0.05). However, the increase
in endogenous OPG was clearly not sufficient to
block RANKL, as indicated by the dramatic increase
in the tumor-induced osteoclastogenesis that was
observed (Fig. 1C; naı̈ve vs. PBS). Murine RANK
mRNA levels were increased approximately twofold
(P¼ 0.06) in tumor-bearing tibias as compared with
The Prostate DOI 10.1002/pros
Fig. 1. OPG-Fc treatment of PC3 tumor bearing mice reduced osteolytic lesion formation, osteoclast numbers, and tumor burden.
A: OPG-Fc treatmentinhibitedprogression of PC3 cell inducedosteolytic lesionsrelative to PBStreatedmice.CB17 SCIDmicewere injected
with1105 PC3 cells intratibially.Micewere treatedwith either PBS or3mg/kghumanOPG-Fc subcutaneously 3weeklybeginning atday7.
X-raysweretakenatdays7,14,21,and24post-injection.Osteolyticregionsareoutlined.Quantificationoflesionsrevealedprogressionover time
in PBS-treatedmicewas significant; P< 0.01for day 24 versus day 7 and P< 0.05 for day 24 versus day14.B: Osteolysis is reduced inOPG-Fc
treatedmicehistologically.Paraffin embedded sectionswere stainedwith hematoxylin and eosin. Arrows indicated areas of osteolysis in PBS
treatedbone.C: OPG-Fc treatmentreduced thenumber of TRAPpositive osteoclasts inbone.Paraffin embedded sectionswere stained for
TRAPactivity (red)andcounterstainedwithhematoxylin.D:PC3 intratibial tumorburdenwasdecreasedinOPG-Fc treatedmice.CB17SCID
micewereinjectedwith1105PC3cellsintratibially.Micewere treatedwitheitherPBSor3mg/kghumanOPG-Fc subcutaneously3weekly
beginning at day 20 and sacrificed on day 27. Paraffin embedded sections were stainedwith hematoxylin and eosin.Tumor area is outlinedby
dashedline.Quantificationof sectionsdemonstrateda significantdecreasein tumorburdeninOPG-Fc treatedmice,P¼ 0.01.
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controls, presumably reflecting the increases in OCL
numbers observed (Fig. 2A). We observed similar
increases in murine RANKL and RANK protein in
histological sections of naı̈ve and tumor bearing bone
(Fig. 2B). In naı̈ve mice, low levels of murine RANKL
expression were detected using immunohistochemis-
try in stromal cells and preosteoblasts. Tumor bearing
mice demonstrated an increase in RANKL positive
stromal cells located at the tumor/bone interface and
within the tumor (Fig. 2B). Using IHC and antibodies
against RANK, a small increase in the number of
RANK positive cells, specifically mature osteoclasts
and osteoclast precursors, was observed in tumor
bearing mice.
We also determined the effect of PC3 tumor
cell growth in vivo on systemic levels of murine
RANKL and OPG. Serum murine RANKL in PC3
tumor-bearing mice was increased approximately
sixfold over that of naı̈ve mice (Fig. 2C, P< 0.0001).
Serum murine OPG levels were increased less than
twofold (Fig. 2C, P< 0.05). Although PC3 cells secrete
OPG in vitro, human OPG was undetectable in the
serum (data not shown). These alterations in
murine RANKL and OPG levels resulted in a fivefold
increase in the RANKL/OPG molar ratio in serum of
tumor-bearing versus control animals (data not shown,
P< 0.01).
To test the hypothesis that RANKL is a critical
mediator of the tumor-induced osteoclastogenesis, we
evaluated the ability of a RANKL inhibitor, recom-
binant human OPG-Fc, to block the progression of
osteolytic lesions in bone. In contrast to the increase
in skeletal lesions observed in PBS treated, tumor-
bearing animals, mice that were treated with OPG-Fc
(3mg/kg, 3 times/week) beginning at day 7 showedno
evidence of osteolytic lesions (Fig. 1A,B). Treatment
with OPG-Fc eliminated tumor-induced osteoclasts
(Fig. 1C) and significantly decreased tumor burden
(Fig. 1D,P¼ 0.01). These data support amodel inwhich
tumor-associated factors converge on the mouse
stroma to cause local increases in RANKL, in turn
leading to the dramatic increases in osteoclasts.
RANKIs Expressedon Prostate CancerCell Lines
Our results indicate a role for the tumor-induced
stromal RANKL in osteolytic lesion development
after PC3 tumor establishment in the skeleton. The
functional role of RANK on mammary epithelial cells
[25] and tumors of epithelial origin [19,26,20] suggests
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Fig. 2. PC3 tumorgrowth invivoresulted in increases in local and systemicRANKL.A:MurineRANKL andOPGmRNAexpressionwere
increasedin tumor-bearing tibias.RNAwasisolated fromtumor-bearing andnon-tumor-bearing tibias 21days afterPC3cell injection.Murine
RANKL,OPG,andRANKexpressionwasdeterminedbyquantitativereal-timeRT-PCRandis shownrelative tob-actinfromthesamesample;
P< 0.01 for RANKL tumor- versus non-tumor-bearing tibia, P< 0.05 for OPG, P¼ 0.06 for RANK.B: Murine RANKL protein expression
wasincreasedinthestromaofPC3tumorbearingmice.ParaffinembeddedsectionswerestainedforRANKLorRANK(inbrown)andcounter-
stained with hematoxylin.C: Serummurine RANKL and OPG levels were increased in PC3-tumor bearingmice. Serum levels of RANKL
and OPG in PC3 tumor-bearing mice and age-matched na|« ve controls were measured by ELISA; P< 0.0001 for RANKL na|« ve versus
tumor-bearingmice,P< 0.05 forOPG.
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that stromal RANKL could also contribute to skeletal
metastasis via direct activation of RANK expressed by
tumor cells. We examined several prostate cancer
cell lines established from primary tumor (22Rv1) or
metastases to lymph node (LNCaP), brain (DU145),
or bone (PC3, MDAPCa2b, C42B) for RANK expres-
sion. These six lines represent androgen-dependent
(LNCaP, 22Rv1, and MDAPCa2b) and androgen-
insensitive (PC3, DU145, C42B) prostate cancers
[27,28]. RANK mRNA was detected by quantitative
real-time RT-PCR in LNCaP, DU145, C42B, and PC3
cells (Fig. 3A). We did not observe RANK mRNA
expression in 22Rv1 and MDAPCa2b cell lines (data
not shown). Since a functional response to RANKL
requires expression of RANK on the cell surface we
used flow cytometry to examine these prostate lines
for RANK. LNCaP, DU145, C42B, and PC3 cells all
expressed RANK on the cell surface, with PC3 cells
showing particularly high levels (Fig. 3B). These data
demonstrate RANK expression in prostate cancer cell
lines derived from a variety of stages of disease.
RANKLInducesMultiple Signaling
Pathways in PC3Cells
RANK activation has been shown to lead to down-
stream signaling events including mitogen-activated
protein (MAP) kinase p38, extracellular signal-
regulated kinase (ERK), c-Jun NH2 kinase (JNK), and
NF-kB pathways [20,29–31]. Treatment of PC3 cells
with RANKL resulted in rapid (within 5 min) stimu-
lation of MAP kinase p38 and ERK phosphorylation
(Fig. 4A). RANKL-dependent JNK phosphorylation
occurred 15min after treatment (Fig. 4A).Weexpanded
upon these findings by investigating the ability of
RANKL to induce signaling events downstream of
MAP kinase p38 and JNK. Within 15 min of RANKL
exposure, phosphorylated forms of MAP kinase p38,
c-Jun, and ATF-2 translocated to the nucleus (Fig. 4B),
confirming the activation of MAP kinase p38 and JNK
signaling pathways by RANKL.
RANKSignaling Results in Changes in
Global Gene Expression in PC3Cells
To further characterize the consequences of RANK
activation in PC3 cells, we performed gene expression
analysis using the Affymetrix U133A chip on PC3 cells
treated with 1 mg/ml RANKL for 6, 12, or 24 hr. We
identified genes that were regulated by RANKL
activation of RANKat each timepoint, with the greatest
number and magnitude of changes in expression
observed at 24 hr (Table I and data not shown).
Analysis of bioduplicate samples of control and
RANKL-treated cells at 24 hr resulted in identification
of 52 probe sets (representing 42 genes) regulated
greater than twofold with P< 0.05. The expression of
35 probe sets (representing 28 genes) was increased in
the presence of RANKL while 17 probe sets represent-
ing 14 genes reflected a decrease in expression.
We chose to focus on genes that had previously been
identified as either regulated by RANKL in other
cell systems (e.g., osteoclasts), increased in disease-
associated osteolysis, or capable of stimulating cell
migration.We looked at genes upregulated in response
to RANKL during osteoclastogenesis (identified in
Chaisson et al. [6]), and studied the regulation of a
subset of these genes in PC3 cells. Using RT-PCR we
confirmed that MMP-9 was upregulated approxi-
mately 25-fold in PC3 cells at 12 hr post-RANKL
stimulation (Fig. 5A). Amongst the factors which have
been implicated in stimulation of osteoclasts and
involvement in osteolysis in disease states (reviewed
in Ref. [15]), we observed the upregulation of CSF-1,
IL-1b, TNF-a, IL-8, and IL-6 by array analysis and
confirmed these gene expression changes by RT-PCR.
The greatest fold induction of IL-6 was 30-fold at 12 hr,
whereas maximal induction of CSF-1, IL-1b, TNF-a,
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Fig. 3. RANKmRNAandproteinwasexpressedinhumanprostatecancercelllines.A:RANKmRNAwasdetectedinprostatecancerlines.
cDNA (10 ng) was subjected to quantitative real-time RT-PCR.RANKexpression is shown relative to b-actin of the same sample.B: RANK
protein was expressed on the surface of prostate cancer cell lines.Cells were stained with RANK-specific antibody or isotype control and
APC-conjugatedsecondaryantibody,andRANKexpressionwasassessedby flowcytometry.
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and IL-8 was approximately three- to fourfold at 24 hr
after RANKL treatment (Fig. 5A). Array analysis
revealed upregulation of CXCL-1, CXCL-2, CXCL-3,
CXCL-5, CXCL-6, and IL-8, members of the C-X-C
chemokine family which can stimulate migration and
chemotaxis of tumor and immune cells [32,33]. Using
RT-PCR analysis, we confirmed that CXCL-1, CXCL-2,
CXCL-3, CXCL-5, CXCL-6, and IL-8 were upregulated
3- to 12-fold in PC3 cells stimulated for 24 hr with
RANKL (Fig. 5A).
We expanded upon the observed gene expression
changes by confirming the regulation of protein levels
using cytokine specific ELISAs. Analysis of the con-
ditionedmedia of PC3 cells 24 hr post-stimulationwith
RANKL demonstrated that CXCL-1, CXCL-5, CXCL-6,
IL-6, and IL-8 protein levels were increased three- to
fourfold (Fig. 5B). We expanded on these findings
by using a multiplex ELISA to analyze the levels of
29 different cytokines in PC3 conditioned media
after RANKL treatment. We identified two additional
proteins, GM-CSF and VEGF-A, in the cytokine panel
that were increased in response to RANKL but had not
been previously identified by array analysis (Fig. 5B).
These observed RANKL-dependent protein changes
were abrogated by the addition of OPG-Fc (data not
shown). Upregulation of these cytokines was also
stimulated by an agonistic antibody to RANK (data
not shown). Together these data support the idea
that RANKL-induced changes on PC3 cells were
specifically via stimulation ofRANKon the tumor cells.
RANKLStimulates Invasion of
PC3CellsThroughCollagen
Previous work has shown that RANKL increases
the survival of osteoclasts [11] and is important for
the proliferation and survival of mammary epithelial
cells during pregnancy [25]. To investigate the pro-
metastatic effects of RANK stimulation on prostate
cancer cells, we studied the effect of RANKL treatment
on PC3 cell proliferation, viability, and cell invasion.
Under a variety of conditions, RANKL did not
detectably alter PC3 cell proliferation in vitro (data
not shown). Additionally, RANKL treatment did not
affect the sensitivity of PC3 cells to a variety of
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Fig. 4. RANKL mediated activation of multiple signaling pathways in PC3 cells.A: RANK activation resulted in phosphorylation of MAP
kinasep38,ERK,andJNK.PC3cellswerestimulatedwith1mg/mlRANKLfor thetimesindicated.Wholecelllysate(15mg)wasusedforimmuno-
blot analysis of the indicatedproteins.B: RANKactivation resulted in translocation of thephosphorylated forms of p38, c-Jun, and ATF-2 to
thenucleus.Cellswere stimulatedwith1mg/mlRANKLfor the timesindicated, thenfixedandimmunostainedfor thephosphorylated formsof
p38, c-Jun, or ATF-2.Cellomics softwarewas used to determine the differencebetween themean fluorescence intensity (MFI) of the nucleus
versus theMFIof thecytoplasm.
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TABLE I. GenesDifferentially Regulatedin Response to RANKL
Accession id Probe set Gene name Gene description
Fold
change P-value
NM_002994 215101_s_at CXCL5 Chemokine (C-X-C motif) ligand 5 18.19 1.86E-10
NM_017870 218834_s_at TMEM132A Transmembrane protein 132A 15.30 0.00145
NM_003900 213112_s_at SQSTM1 Sequestosome 1 14.76 0.00164
NM_001165 210538_s_at BIRC3 Baculoviral IAP repeat-containing 3 10.14 7.88E-15
NM_002994 214974_x_at CXCL5 Chemokine (C-X-C motif) ligand 5 8.69 3.49E-14
NM_000584 211506_s_at IL8 Interleukin 8 7.63 4.35E-07
NM_006850 206569_at IL24 Interleukin 24 7.33 0.00058
NM_015541 211596_s_at LRIG1 Leucine-rich repeats and immunoglobulin-like domains 1 6.50 0.00035
NM_004666 205844_at VNN1 Vanin 1 5.34 0.00085
NM_016584 220054_at IL23A Interleukin 23, alpha subunit p19 4.82 1.36E-19
NM_016235 203632_s_at GPRC5B G protein-coupled receptor, family C, group 5, member B 4.45 8.91E-07
NM_002089 209774_x_at CXCL2 Chemokine (C-X-C motif) ligand 2 4.17 1.15E-09
NM_020529 201502_s_at NFKBIA Nuclear factor of kappa light polypeptide gene enhancer in
B-cells inhibitor, alpha
3.96 7.87E-21
NM_002638 203691_at PI3 Peptidase inhibitor 3, skin-derived (SKALP) 3.39 2.67E-07
NM_002090 207850_at CXCL3 Chemokine (C-X-C motif) ligand 3 3.15 0.00335
NM_001077493 207535_s_at NFKB2 Nuclear factor of kappa light polypeptide gene enhancer in
B-cells 2
3.02 5.16E-07
NM_002192 204926_at INHBA Inhibin, beta A (activin A, activin AB alpha polypeptide) 2.90 1.70E-06
NM_000043 215719_x_at FAS Fas (TNF receptor superfamily, member 6) 2.85 0.00153
NM_000584 202859_x_at IL8 Interleukin 8 2.81 1.05E-18
NM_006290 202644_s_at TNFAIP3 Tumor necrosis factor, alpha-induced protein 3 2.75 1.00E-10
NM_002993 206336_at CXCL6 Chemokine (C-X-C motif) ligand 6 2.67 9.88E-17
NM_014903 204823_at NAV3 Neuron navigator 3 2.52 0.00317
NM_000576 205067_at IL-1b Interleukin 1, beta 2.37 7.72E-22
NM_006058 207196_s_at TNIP1 TNFAIP3 interacting protein 1 2.34 6.95E-12
NM_001511 204470_at CXCL1 Chemokine (C-X-C motif) ligand 1 2.31 3.18E-19
NM_005257 210002_at GATA6 GATA binding protein 6 2.30 6.80E-09
NM_001945 38037_at HBEGF Heparin-binding EGF-like growth factor 2.22 0.00152
NM_000593 202307_s_at TAP1 Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 2.22 0.00228
NM_001109 205180_s_at ADAM8 ADAM metallopeptidase domain 8 2.19 0.00004
NM_006290 202643_s_at TNFAIP3 Tumor necrosis factor, alpha-induced protein 3 2.19 0.00064
NM_000576 39402_at IL-1b Interleukin 1, beta 2.15 5.78E-21
NM_002638 41469_at PI3 Peptidase inhibitor 3, skin-derived (SKALP) 2.15 7.90E-08
NM_003900 201471_s_at SQSTM1 Sequestosome 1 2.14 2.53E-11
NM_002192 210511_s_at INHBA Inhibin, beta A (activin A, activin AB alpha polypeptide) 2.02 4.31E-10
NM_006509 205205_at RELB v-rel reticuloendotheliosis viral oncogene homolog B, (avian) 2.01 0.00255
NM_003713 212226_s_at PPAP2B Phosphatidic acid phosphatase type 2B 2.02 1.49E-09
NM_003286 208900_s_at TOP1 Topoisomerase (DNA) I 2.02 2.94E-09
NM_003607 214464_at CDC42BPA CDC42 binding protein kinase alpha (DMPK-like) 2.02 9.00E-07
NM_001006946 201286_at SDC1 Syndecan 1 2.06 1.02E-14
NM_005242 206429_at F2RL1 Coagulation factor II (thrombin) receptor-like 1 2.06 3.02E-06
NM_001394 204015_s_at DUSP4 Dual specificity phosphatase 4 2.08 7.55E-08
NM_002275 204734_at KRT15 Keratin 15 2.11 0.00415
NM_018897 214222_at DNAH7 Dynein, axonemal, heavy chain 7 2.16 0.00056
NM_003713 209355_s_at PPAP2B Phosphatidic acid phosphatase type 2B 2.30 1.70E-06
NM_001394 204014_at DUSP4 Dual specificity phosphatase 4 2.42 1.31E-17
NM_000860 211548_s_at HPGD Hydroxyprostaglandin dehydrogenase 15-(NAD) 2.67 7.57E-07
NM_001040708 218839_at HEY1 Hairy/enhancer-of-split related with YRPW motif 1 2.68 3.56E-12
NM_000489 208859_s_at ATRX RAD54 homolog, S. cerevisiae 2.68 5.86E-06
XM_001128030 213605_s_at LOC728411 Similar to Beta-glucuronidase precursor 2.89 0.00496
NM_000599 211959_at IGFBP5 Insulin-like growth factor binding protein 5 3.02 1.03E-19
NM_006408 209173_at AGR2 Anterior gradient 2 homolog (Xenopus laevis) 3.16 6.76E-07
NM_000599 203424_s_at IGFBP5 Insulin-like growth factor binding protein 5 6.10 9.39E-08
Genes regulated by RANKLwith greater than twofold expression differences relative to untreated cells and their associated P-values are
shown. Affymetrix probe set identifiers, gene descriptions, and gene accession numbers are included.
chemotherapeutics, including, CPT-11, doxorubicin,
5-Florouracil, etoposide, or cisplatin (data not shown).
RANKL has been shown to stimulate chemotaxis of
osteoclast-like cells and RANK-expressing tumor cells
[19,34,35]. Given that RANKL is expressed in the bone
microenvironment andPC3 tumor cells expressRANK,
we hypothesized that RANKL might serve as a ‘‘soil’’
factor that stimulates migration of PC3 cells to bone.
We studied the effect of RANKL on invasion of
PC3 cells through a collagen matrix and found that
invasion was increased significantly in the presence
of RANKL (Fig. 6, P< 0.05 RANKL treated versus
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Fig. 5. RANKLinducedchanges ingene expressionwere confirmedat themRNAandprotein levels.A:mRNAlevels of genesidentifiedby
array were increased in response to RANKL. mRNAwas isolated from PC3 cells12 hr (MMP-9, IL-6) or 24 hr (all other genes) after RANKL
treatment.Geneexpressionwasdeterminedbyquantitativereal-timeRT-PCR,normalizedtob-actinandexpressedrelativetountreatedcells.
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Fig. 6. RANKLstimulatedmigrationofPC3cells throughcollagenmatrix.PC3cellswere seededinto theuppercompartmentof two-layer
chamberinvasionplates thatwereseparatedbyanuncoatedmembrane(forbaselinecontrol)or amembranecoatedwithcollagenmatrix.The
cellswereculturedfor48hr followedbystainingof themembranewithaDiff-Quikstainkit.Thenumberofcells thatpenetratedthemembrane
was counted in fivemicroscopic fields (at 200magnification) per filter. Invasive ability was defined as the proportion of cells that invaded
thematrix-coatedmembrane dividedby thenumber of cells thatmigrated through theuncoatedmembrane (baselinemigration).The results
arereportedas themeanofduplicateassays. *P< 0.05 for100ng/mlRANKLversuscontrolandOPGtreatedsamples.
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control). RANKL induced invasion occurred in a dose-
dependent manner (data not shown). Invasion of PC3
cells through collagen was blocked by the addition of
OPG, indicating that RANKL activation of RANK is
sufficient to lead to invasion (Fig. 6, P< 0.05 RANKL
treated vs. OPG treated). This data demonstrates that
RANKL stimulated invasion of PC3 cells in vitro and
supports the hypothesis that RANKL may serve as a
chemoattractant factor for RANK-expressing tumor
cells in vivo.
DISCUSSION
A universal attribute that distinguishes cancer cells
that have a highpropensity tometastasize to the bone is
their ability to initiate or accelerate bone remodeling.
There is considerable experimental evidence that the
co-opted bone microenvironment provides reciprocal
feedback to support tumor growth and occurs in both
osteolytic and osteoblastic bone metastases (reviewed
in Ref. [15]).
In this study, we observed that PC3 prostate tumor
co-opt the critical processes that govern osteoclasto-
genesis. We observed that interaction of PC3 cells with
the bone microenvironment results in excessive
RANKL levelswithin the bone stroma and an increased
ratio ofRANKL toOPGat local and systemic levels. The
operative role of RANKL in PC3 tumor-induced
osteoclastogenesis and bone lesions was proven by
blocking RANKL in vivo with OPG-Fc which elimi-
nated tumor-induced osteoclastogenesis and reduced
skeletal lesions. Importantly, we also demonstrate
that RANK is expressed in prostate tumor cell
lines derived from different metastatic sites and from
both androgen-dependent and androgen-independent
tumors. RANKL can directly activate RANK on tumor
cells as was shown by the stimulation of several
biochemical signaling pathways in PC3 cells. More-
over, we demonstrate that RANKL stimulation alters
the expression of genes involved in chemotaxis,
migration, and invasion of cancer cells. These effects
at 24hrmay reflect thedirect activationofRANKorbe a
consequence of a cascade of downstream factors
initiated by RANKL stimulation. The data suggest
that RANKL may stimulate tumor cell metastases.
This hypothesis is supported by our observation that
RANKL can activate the invasive/metastatic behavior
of PC3 cells in vitro.
The critical involvement of RANKL in bone lesion
formation and progression of prostate tumor growth
within the skeleton has been well established in animal
models of prostate cancer bone metastasis. Pharmaco-
logical inhibition of RANKL using recombinant con-
structs of either OPG-Fc or RANK-Fc in these models
reduces tumor induced osteoclast numbers [18,36–38].
The reduction in osteoclastic activity presumably also
blocks the release of growth factors [e.g., including
transforming growth factor b (TGF-b), fibroblast growth
factors (FGFs), platelet-derived growth factors (PDGFs),
bone morphogenic proteins (BMPs), and insulin-like
growth factor (IGF-1)] from the bone which normally
would stimulate tumor growth. Thus, one mechanism
by which RANKL inhibition reduces skeletal tumor
burden is indirect, via inhibition of osteoclast activity
and reduction of bone-derived growth factors [37–39].
Thedependency of this effect on the bonemicroenviron-
ment is supported by the observation that RANKL
inhibitionwithOPG-Fc orRANK-Fcdoes not reduce the
tumor growth of subcutaneously implanted prostate
cancer cells [21,37,38].
While RANK expression has been primarily
observed on osteoclasts, recent studies have demon-
strated RANK expression on tumor cells, including
breast, prostate, and melanoma cancer cell lines
[19,20,26,40,41]. The ability of RANKL to act directly
on RANK-expressing tumor cells that we observe in
this study is consistent with a recently described role
for RANKL in migration of prostate tumor cells [20]
or other tumor cells [19]. Given the stimulation of
tumor cell migration by RANKL, the authors of this
study suggest that the rich source of RANKLwithin the
bone may serve as a soil factor which attracts RANK-
expressing tumor cells. To test this hypothesis, Jones
et al., inhibited RANKL in a bone metastasis model in
which the RANK-expressing melanoma does not lead
to osteoclastic activation. The observed decrease in
tumor growth in long bones with RANKL inhibition
(using OPG-Fc) but not bisphosphonates, which sup-
press osteoclast activation, suggests that RANKL may
act directly on tumor cells presumably via activation of
cell migration [19].
In our own study we observed that RANKL
inhibition with OPG-Fc reduced not only tumor-
induced osteoclastogenesis and osteolytic lesions but
also reduced PC3 skeletal tumor burden in a setting in
which skeletal tumor and lesions were already estab-
lished prior to treatment. Based on our observations of
direct activation of RANK-expressing tumor cells by
RANKL and the increased stromal levels of RANKL
observed after PC3 interaction with the bone, there is
potential for OPG-Fc to have a direct inhibitory effect
on tumor cells. However, it is difficult to distinguish
between direct and indirect effects of RANKL inhibi-
tion in vivo because of the degree of osteolysis induced
by the tumor cells. Oneway inwhich OPG-Fc probably
acts to reduce PC3 skeletal tumor burden is via indirect
action on the bonemicroenvironment and interruption
of the skeletal support of tumor growth. The identi-
fication in this current study of specific molecular
markers of RANKL response in the PC3 cells (e.g.,
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biochemical pathways, mRNA) will facilitate the
development of pharmacodynamicmarkers ofRANKL
inhibition that can be used to demonstrate a direct
effect of RANKL inhibition on the tumor cell. These
experiments are currently underway.
Prostate tumorswill give rise to a heterogeneousmix
of blastic and lytic bone lesions in patients suggesting
the activation of both osteoblast and osteoclasts.
However, analysis of the critical osteoclastic regulatory
proteins, RANKL and OPG, has not shown a correla-
tion between expression and severity of bone disease.
For instance, serum OPG is increased in patients with
bone metastases relative to patients with non-osseous
metastases and primary tumors [42–45]. Given that the
majority of prostate cancer patients with bone meta-
stasis have elevated bone remodeling [7,8] the increase
in OPG may be a compensatory response to skeletal
remodeling or a consequence of the increased tumor
burden. In patients with prostate cancer bone meta-
stases, there is considerable evidence of tumor-induced
osteoclastogenesis [7,8], however whether the main
source of RANKL is from the tumor itself or the bone
stroma is somewhat controversial. There are now three
studies of clinical prostate bone metastasis using
immunohistochemical staining for RANKL and OPG
that have revealed expression in prostate tumor
cells, but not the bone stroma surrounding the tumor
[26,46,47]. In our own observations in this animal
model of prostate cancer-induced lesions we clearly
demonstrate an excessive RANKL/OPG ratio that can
be observed at the local and systemic level. Through the
use of species-specific PCR primers and antibodies,
we show that the host contributes to the majority of
RANKL and OPG changes, including a significant
increase in stromal RANKL levels, while the tumor cell
production of these factors is not significantly altered at
the end of study (day 21). We report an increase in the
mouse RANKL/OPG ratio, which is consistent with
data from other observations in which osteolysis is
present in disease settings [48]. The discrepancy
between these clinical data [26,46,47] and our own
presented here may be due in part to the PC3 model
representing an extreme osteolytic response to prostate
cancer while in patients there is a greater contribution
of osteoblastic lesions. Alternatively, the poor sensi-
tivity and technical challenges of immunohistochem-
ical analysis of RANKL expression in decalcified
clinical bone sections that provide obstacles to specific
RANKL detection are not problematic in the PC3
bone metastases model. In fact these earlier findings of
RANKL-positive prostate cancer cells within bone
metastases have not been confirmed and more recent
studies in clinical samples indicate thatRANKLprotein
is elevated in the bone stroma [49]. It is formally
possible that the PC3 cells did express RANKL at an
earlier point prior to day 21 that was not addressed in
our own study. Either human or mouse RANKL (or
both) must be operating at an early point to cause
osteolysis, since the RANKL inhibitor OPG-Fc blocked
theprogression of PC3-inducedx-ray lesions fromdays
7 to 14 (Fig. 1A). Irrespective of the source of RANKL,
RANKL inhibitors should reduce the tumor-induced
osteoclastogenesis, as was clearly demonstrated in the
current study.
Altogether, these data underscore the functional
importance of a dysregulated RANK/RANKL/OPG
axis in the pathophysiology of prostate cancer bone
metastasis. Moreover, these data substantiate the newly
established direct role for RANKL in the metastatic/
invasive activity of tumor cells and support further
studies in vivo on the role ofRANKLandRANK inbone
metastases.
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